Building Life

Founded in 2013, Arcturus is a leader in RNA medicines.

Placeholder

Arcturus Therapeutics

  • Synthetic GenomicsArcturus Therapeutics Announces Strategic Alliance with Synthetic Genomics, Inc. to develop self-amplifying RNA-based vaccines and therapeuticsREAD MORE
  • Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA MedicinesREAD MORE
  • Arcturus Therapeutics to Receive Up to $3 Million from Cystic Fibrosis Foundation Therapeutics to Advance a Novel LUNAR-Formulated mRNA CFTR TherapeuticREAD MORE
  • Takeda Pharmaceuticals logoTakeda Pharmaceuticals entered into collaboration with Arcturus Therapeutics to develop RNA-based therapeutics for the treatment of NASH.READ MORE
  • Ultragenyx Pharmaceutical Inc. entered into a research collaboration and license agreement with Arcturus to discover and develop messenger RNA (mRNA) therapeutics.Ultragenyx Pharmaceutical Inc. entered into a research collaboration and license agreement with Arcturus to discover and develop messenger RNA (mRNA) therapeutics.READ MORE

Proprietary Technologies

UNA and LUNAR™ have the Potential to Revolutionize RNA Medicines

TRANSPORTERS RECEPTORS ANTIBODIES ENZYMES TALEN GPCR’S HORMONES CHAPERONES CAR-T CRISPR
Trans-membrane Proteins Secreted Proteins Intracellular Proteins Engineered Antigens Engineered Nucleases
READ MORE

RNA Medicines

  • mRNA
    Messenger RNA (mRNA) therapeutics can treat diseases caused by a lack of protein, or by defective proteins, such as Duchenne muscular dystrophy and cystic fibrosis. READ MORE
  • Gene Editing
    Human DNA has roughly 20 000 genes. Each gene contains the code needed to make one or more proteins. READ MORE
  • RNA Replicon
    RNA replicons provide the genetic instructions to the body’s own cells to produce ample amounts of protein and unleash an immune response. READ MORE
  • siRNA
    Small interfering RNA (siRNA) medicines can treat viral infections like hepatitis B and diseases like Huntington’s disease that are caused by malfunctioning proteins. READ MORE
  • MicroRNA
    MicroRNA medicines can be used to treat complex diseases like cancer that are caused by many different malfunctioning proteins. READ MORE
  • RNA
    RNA medicines can target any gene or protein in humans and so can be used to treat diseases that cannot be treated by conventional drugs such as small molecules and biologics. READ MORE
  • RNAi
    RNA interference (RNAi) is a natural mechanism used by the body to turn genes off without permanently changing DNA. READ MORE
  • Antisense RNA
    Antisense RNA works by binding to messenger RNA (mRNA) and physically preventing the cell from translating the mRNA into protein. READ MORE

Pipeline

name

LUNAR-OTC

indication
OTC Deficiency
api
Nucleic Acid

INTERNAL mRNA PROGRAM

PRECLINICAL

name

LUNAR-RLD

indication
Rare Liver Disease
api
Nucleic Acid

INTERNAL mRNA PROGRAM

PRECLINICAL

name

LUNAR-HBV

indication
Hepatitis B
api
Nucleic Acid

PARTNERED PROGRAM

RESEARCH

name

LUNAR-TKD

indication
NASH
api
Nucleic Acid

PARTNERED PROGRAM

RESEARCH

name

LUNAR-RARE1

indication
Undisclosed Rare Disease
api
Nucleic Acid

PARTNERED mRNA PROGRAM

RESEARCH

name

LUNAR-RARE2

indication
Undisclosed Rare Disease
api
Nucleic Acid

PARTNERED mRNA PROGRAM

RESEARCH

name

LUNAR-CF

indication
Cystic Fibrosis
api
Nucleic Acid

INTERNAL mRNA PROGRAM

PRECLINICAL

name

LUNAR-RPL

indication
Vaccines
api
RNA Replicon

PARTNERED PROGRAM

RESEARCH

name

LUNAR-TTR

indication
TTR Amyloidosis - Partnering Discussions ongoing
api
Nucleic Acid

INTERNAL siRNA PROGRAM

PRECLINICAL

name

Arbutus, ARB-1467

indication
Hepatitis B
api
UNA Oligomers

PARTNERED PROGRAM

CLINICAL

News & Events

  • November 16, 2017

    Arcturus Therapeutics Announces Completion of Merger with Alcobra Ltd. and Commences Trading on the Nasdaq Global Market

    • November 16 2017
    • 0
    read more
  • November 16, 2017

    Arcturus Therapeutics Announces Completion of Merger with Alcobra Ltd. and Commences Trading on the Nasdaq Global Market

    • November 16 2017
    • 0
    read more
  • November 2, 2017

    Arcturus Therapeutics to Host Key Opinion Leader Call on Advances in Delivery of Nucleic Acid Medicines on Tuesday, November 7

    • November 2 2017
    • 0
    read more
  • October 31, 2017

    Arcturus Therapeutics and Synthetic Genomics Announce Strategic Alliance to Develop Next-Generation Vaccines and Therapeutics

    • October 31 2017
    • 0
    read more
  • October 30, 2017

    Arcturus Therapeutics to Present at NY/NJ CEO Conference on Nov 8th

    • October 30 2017
    • 0
    read more
  • October 30, 2017

    Arcturus Therapeutics to Present at the 2017 North American Cystic Fibrosis Conference on Nov 2nd

    • October 30 2017
    • 0
    read more
  • October 30, 2017

    Arcturus Therapeutics to Present at the 5th International mRNA Health Conference on Nov 1st

    • October 30 2017
    • 0
    read more
  • October 26, 2017

    Arcturus Therapeutics Announces Presentations at Conferences in November

    • October 26 2017
    • 0
    read more
  • October 19, 2017

    Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines

    • October 19 2017
    • 0
    read more